Subscribe
Subscribe

Belgium, Flanders

Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications

Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of the Board. The company also expands the Scientific Advisory Board with clinical experts to support broader therapeutic applications, exploring the potential of novel HDAC6 inhibitors in Charcot-Marie-Tooth disease (CMT), and now also in other indications such as chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS).

miDiagnostics launches its CE-IVD certified ultra-fast COVID-19 PCR test

IBA and SCK CEN partnership to produce rare radioisotope for cancer treatments

The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.

VIB: a new focus on data science with Christine Durinx at the helm

Christine Durinx has been appointed as the new co-Managing Director of the world-class life sciences research institute VIB. Taking over from Jo Bury, Durinx joins VIB’s other co-Managing Director Jérôme Van Biervliet in ushering in a new era of discoveries increasingly driven by data science.

Christine Durinx joins VIB as co-managing director

Belgium, 20 April 2022 – VIB and Flemish Minister of Economy and Innovation Hilde Crevits announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics. Her appointment strengthens VIB’s commitment to focus on the burgeoning fields of data science and personalized health.

V-Bio Ventures raises EUR 110 million for its second fund and expands team

Ghent, Belgium, 31 March 2022 – V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having raised EUR 110 million euro and exceeding its target of EUR 100 million.

Solvay Brussels School of Economics and Management joins forces with the Belgian life sciences ecosystem to train the next generation of Biotech and MedTech leaders

miDiagnostics welcomes Nicolas De Clercq as its new Chief Financial Officer

Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth

New incubator biotope by VIB launches to support biotech startup teams on their journey to success

Qbic announces first close of new fund at EUR 49 million to invest in spin-offs from world-class knowledge partners

Abscint labels antibodies with radioactive material to spot harmful cells

Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.

RE-Place project: Reducing animal research through alternative methods

If scientists could stop animal testing, most would do so immediately. So why is it taking so long to develop alternatives to animal testing? And what are we doing to speed up the process?

V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals

flanders.healthTech launches 14 unique innovation projects in healthcare

Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 consortia have started working on innovation projects in healthcare. The projects have received a total of EUR 4.7 million in VLAIO support from Flemish Minister of Economy and Innovation Hilde Crevits to help make a difference in the field of technology and innovation in healthcare.